Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2
Menstrual blood loss: mean loss · women with heavy menstrual bleeding
1 finding from 1 review
- no estimate extracted3 studies · 312 participantsVery low
Findings
What do systematic reviews say?
31 questions · 32 findings · 2 reviews
No studies found 8 · 25%GRADE not reported 4 · 12.5%Very low 11 · 34.4%Low 7 · 21.9%Moderate 2 · 6.3%High 0 · 0%
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2
Menstrual blood loss: improvement rates · women with heavy menstrual bleeding
Antifibrinolytics may leads to higher menstrual blood loss: improvement rates (overall) compared with progestogens (low certainty).
1 finding from 1 review
- RR 1.54 [1.31, 1.8]5 studies · 422 participantsLow
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2
Adverse events (any) · women with heavy menstrual bleeding
Antifibrinolytics may leads to lower adverse events (any) compared with progestogens (low certainty).
1 finding from 1 review
- RR 0.66 [0.46, 0.94]4 studies · 349 participantsLow
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2
Thromboembolic events · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs NSAIDs
Menstrual blood loss: mean loss · women with heavy menstrual bleeding
1 finding from 1 review
- no estimate extracted1 study · 49 participantsLow
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo
Number of participants with any bleeding · People with a haematological disorder
1 finding from 1 review
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes onlyno estimate extracted1 study · 56 participantsVery low
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo
Thromboembolism · People with a haematological disorder
1 finding from 1 review
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 68 participantsVery low
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo
Quality of life ‐ not reported · People with a haematological disorder
1 finding from 1 review
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported